Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Capecitabine

Capecitabine Am J Cancer 2005; 4 (5): 324-325 GUEST COMMENTARIES 1175-6357/05/0005-0324/$34.95/0 © 2005 Adis Data Information BV. All rights reserved. infusional fluorouracil and folinic acid improves at least dis- ease-free survival in stage III patients. Similarly capecitabine, an A Viewpoint by Joe McKendrick oral fluoropyrimidine, has been shown to be at least as effective in Department of Haematology and Medical Oncology, Box Hill reducing cancer relapses as the standard Mayo Clinic regimen in Hospital, Box Hill, Victoria, Australia the recently reported Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial. A significant difference in relapse-free survival in The treatment of colorectal cancer has undergone a revolution stage III patients was seen in this study and, perhaps most impor- over the past two decades with the advent of effective adjuvant tantly, a greatly improved serious toxicity profile with a preferred therapy for resected colon cancer and adjuvant and neoadjuvant means of administration. therapy for rectal cancer. More recently, the application of effec- Should patients receive multiagent chemotherapy or single- tive new chemotherapeutic and biologic agents has seen the medi- an survival of patients with metastatic colorectal cancer approach agent capecitabine? The data support single-agent capecitabine as 2 years. A problem that has http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Capecitabine

Abstract

Am J Cancer 2005; 4 (5): 324-325 GUEST COMMENTARIES 1175-6357/05/0005-0324/$34.95/0 © 2005 Adis Data Information BV. All rights reserved. infusional fluorouracil and folinic acid improves at least dis- ease-free survival in stage III patients. Similarly capecitabine, an A Viewpoint by Joe McKendrick oral fluoropyrimidine, has been shown to be at least as effective in Department of Haematology and Medical Oncology, Box Hill reducing cancer relapses as the standard Mayo Clinic regimen in...
Loading next page...
 
/lp/springer-journals/capecitabine-dbrYmDetE0
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504050-00006
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2005; 4 (5): 324-325 GUEST COMMENTARIES 1175-6357/05/0005-0324/$34.95/0 © 2005 Adis Data Information BV. All rights reserved. infusional fluorouracil and folinic acid improves at least dis- ease-free survival in stage III patients. Similarly capecitabine, an A Viewpoint by Joe McKendrick oral fluoropyrimidine, has been shown to be at least as effective in Department of Haematology and Medical Oncology, Box Hill reducing cancer relapses as the standard Mayo Clinic regimen in Hospital, Box Hill, Victoria, Australia the recently reported Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial. A significant difference in relapse-free survival in The treatment of colorectal cancer has undergone a revolution stage III patients was seen in this study and, perhaps most impor- over the past two decades with the advent of effective adjuvant tantly, a greatly improved serious toxicity profile with a preferred therapy for resected colon cancer and adjuvant and neoadjuvant means of administration. therapy for rectal cancer. More recently, the application of effec- Should patients receive multiagent chemotherapy or single- tive new chemotherapeutic and biologic agents has seen the medi- an survival of patients with metastatic colorectal cancer approach agent capecitabine? The data support single-agent capecitabine as 2 years. A problem that has

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.